MRI, Genes and Single-Cell Data Point to Vulnerable Brain Regions in ALS

Amyotrophic lateral sclerosis has long been defined by the death of motor neurons in the brain and spinal cord, yet the molecular reasons why some cortical regions collapse while others resist have remained frustratingly opaque. Now a team of researchers in China has combined high-resolution brain imaging with gene expression atlases and single-cell sequencing to build one of the most detailed maps yet of where and why the ALS cortex begins to thin and shrink. Writing in BMC Medicine, the team, led by Jixin Luan and colleagues at Qilu Hospital of Shandong University, reports that specific cortical changes in patients with sporadic ALS can be traced to candidate genes, including MOBP and ZNHIT3, whose activity patterns align with distinct glial cell populations in the vulnerable regions.

The study began with a straightforward but demanding measurement task. The researchers acquired high-resolution T1-weighted magnetic resonance imaging scans from 73 patients with sporadic ALS and 70 healthy controls, then used the Desikan-Killiany-Tourville atlas to parcellate the cortex into defined regions of interest. For each region they quantified two separate structural phenotypes: cortical surface area, which reflects the sheet-like expansion of the cortex during development, and cortical thickness, which is more closely tied to the density and health of neurons within the cortical column. This distinction matters because surface area and thickness are governed by partly independent genetic programs, and treating them as a single lumped measure can obscure the biology underneath.

The comparisons revealed precise, statistically robust alterations. Patients showed significantly reduced surface area in the left precentral gyrus, the strip of cortex that houses the primary motor neurons whose degeneration drives the muscle wasting and weakness characteristic of ALS. They also showed decreased cortical thickness in the left frontal pole, a region implicated in the cognitive and behavioral changes that frequently accompany the disease, including the frontotemporal dementia spectrum that overlaps clinically with a subset of ALS cases. Both findings survived correction for multiple comparisons across the full cortical parcellation, with false discovery rate adjusted p-values of 0.025, suggesting that the structural signature is not a statistical artifact of scanning dozens of regions simultaneously.

With the anatomical targets established, the team asked a harder question: does the shape of the cortex influence ALS risk, or does the disease reshape the cortex? To address the direction of the relationship, they turned to two-sample Mendelian randomization, a technique that uses genetic variants as naturally randomized instruments to probe causality. The analysis identified nominal associations between ALS risk and several cortical structural phenotypes, including surface area of the paracentral lobule and thickness of the frontal pole. While nominal rather than definitive, these associations are consistent with a model in which cortical architecture and disease susceptibility are intertwined, with certain structural configurations marking regions that are intrinsically more vulnerable to the ALS process.

The next step was the study’s methodological centerpiece: coupling the imaging signatures to gene expression. The researchers drew on the Allen Human Brain Atlas, a postmortem resource that maps the expression of thousands of genes across hundreds of cortical sampling sites, and used partial least squares regression to identify transcriptional programs whose spatial distribution across the cortex mirrors the pattern of surface area and thickness alteration in ALS. They complemented this with a region-wise differential expression analysis to derive intersect gene sets. The result was a catalogue of 215 genes tied to surface area alterations and 979 genes tied to thickness alterations, each representing a molecular fingerprint of the regions that falter in ALS.

Functional enrichment analyses gave these gene sets biological texture. Both sets were enriched in synaptic processes and neuroactive ligand-receptor interaction pathways, pointing to the well-established role of excitatory synaptic dysfunction and glutamatergic signaling in motor neuron degeneration. But the cell-type analysis, performed using expression-weighted cell-type enrichment, produced the study’s most intriguing division. Genes associated with surface area alterations were preferentially expressed in oligodendrocyte-related cell types, the myelin-forming glia that wrap axons and support the metabolic demands of long-range projection neurons. Genes associated with thickness alterations, by contrast, showed astrocyte-related enrichment, implicating the star-shaped support cells that regulate neurotransmitter clearance, blood-brain barrier integrity and metabolic coupling at synapses.

To move from spatial correlation to molecular prioritization, the team deployed summary-data-based Mendelian randomization, or SMR, which integrates genome-wide association study data for ALS with quantitative trait loci that link genetic variants to gene expression and DNA methylation. This approach tests whether the genetic signal associated with a structural phenotype is mediated by altered expression of a nearby gene, effectively triangulating among imaging, genetics and transcriptomics. The analysis nominated two candidate genes: MOBP, associated with the surface area alteration pattern, and ZNHIT3, associated with the thickness pattern. MOBP encodes a myelin-associated protein expressed almost exclusively in oligodendrocytes, fitting neatly with the oligodendrocyte enrichment of the surface area gene set. ZNHIT3, a component of chromatin-remodeling machinery with roles in RNA polymerase transcription, fits less obviously but intriguingly into the astrocyte story.

Independent evidence came from public single-cell RNA sequencing datasets derived from ALS cases carrying the C9orf72 repeat expansion, the most common genetic cause of the disease. In those data, MOBP expression differed significantly in oligodendrocytes, and ZNHIT3 expression was significantly lower in astrocytes, both with p-values below 0.001. The convergence is notable: two genes prioritized through a purely statistical pipeline built on sporadic ALS imaging showed cell-type-specific expression changes in an independent, genetically distinct form of the disease. That cross-validation across modalities and patient populations strengthens the argument that oligodendrocyte dysfunction and astrocyte dysfunction contribute in parallel, and through partly separable molecular routes, to the regional cortical vulnerability observed on MRI.

The findings arrive amid a broader shift in neuroscience toward multimodal data integration. Individual technologies, whether MRI, bulk transcriptomics or single-cell sequencing, each capture only a slice of a disease process that unfolds across scales from molecules to circuits to behavior. By anchoring the analysis to a measurable clinical phenotype, namely region-specific cortical atrophy, and then triangulating across four independent data layers, the study demonstrates a template that could be applied to other neurodegenerative conditions, including Alzheimer’s disease, frontotemporal dementia and Parkinson’s disease, where regional vulnerability is equally striking and equally unexplained. The same framework could also help reconcile why some ALS patients present with pure motor syndromes while others develop early cognitive impairment, potentially reflecting distinct molecular cascades in motor versus frontal cortex.

The authors are careful to frame the work as hypothesis-generating rather than definitive. The imaging cohort was modest in size, the Mendelian randomization associations were nominal, the transcriptomic coupling rests on postmortem atlas data from donors without ALS, and the single-cell evidence comes from a different ALS genotype. Future longitudinal studies tracking cortical structure in at-risk individuals, and experimental models testing whether MOBP and ZNHIT3 perturbation genuinely alters neuronal survival, will be needed to validate biological relevance. Still, by converting an anatomical observation into a shortlist of testable molecular suspects rooted in specific glial cell types, the study offers ALS researchers something the field has lacked: a concrete, data-driven entry point into the question of why the cortex fails where it does, and a roadmap for how imaging genetics can accelerate the search for therapeutic targets in one of medicine’s most relentless diseases.

Subject of Research: Molecular mechanisms of region-specific cortical vulnerability in amyotrophic lateral sclerosis

Article Title: Integrating neuroimaging, transcriptomics and single-cell sequencing identifies candidate molecular features of cortical vulnerability in amyotrophic lateral sclerosis

Article References: Luan, J., Shan, D., Yun, Y., Wang, Y., Ma, M., Wang, H., Ji, X., Jiao, Y., Tang, Y., Li, J., Zhan, Z., Sun, X., Gao, N., Yan, C., Liu, F., Liu, S., & Yu, D. (2026). Integrating neuroimaging, transcriptomics and single-cell sequencing identifies candidate molecular features of cortical vulnerability in amyotrophic lateral sclerosis. BMC Medicine. https://doi.org/10.1186/s12916-026-05247-3

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05247-3

Keywords: amyotrophic lateral sclerosis, cortical thickness, cortical surface area, imaging transcriptomics, Mendelian randomization, SMR, single-cell RNA sequencing, oligodendrocytes, astrocytes, MOBP, ZNHIT3, motor cortex